Tejara Capital Ltd Cuts Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Tejara Capital Ltd decreased its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 42.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 813,550 shares of the company’s stock after selling 607,440 shares during the period. Roivant Sciences comprises approximately 6.2% of Tejara Capital Ltd’s portfolio, making the stock its 2nd biggest holding. Tejara Capital Ltd owned about 0.11% of Roivant Sciences worth $9,624,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Nordea Investment Management AB grew its holdings in shares of Roivant Sciences by 22.5% in the fourth quarter. Nordea Investment Management AB now owns 282,834 shares of the company’s stock worth $3,306,000 after purchasing an additional 52,031 shares during the last quarter. TOMS Capital Investment Management LP bought a new position in shares of Roivant Sciences in the third quarter worth approximately $46,333,000. Barclays PLC grew its holdings in shares of Roivant Sciences by 19.7% in the third quarter. Barclays PLC now owns 459,521 shares of the company’s stock worth $5,302,000 after purchasing an additional 75,609 shares during the last quarter. Loomis Sayles & Co. L P grew its holdings in shares of Roivant Sciences by 13.3% in the third quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company’s stock worth $45,147,000 after purchasing an additional 458,601 shares during the last quarter. Finally, Retirement Systems of Alabama grew its holdings in shares of Roivant Sciences by 26.9% in the third quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock worth $6,116,000 after purchasing an additional 112,286 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Trading Up 1.8 %

Shares of Roivant Sciences stock opened at $10.85 on Tuesday. The firm has a market capitalization of $7.74 billion, a P/E ratio of -72.33 and a beta of 1.26. The business has a fifty day simple moving average of $10.80 and a two-hundred day simple moving average of $11.49. Roivant Sciences Ltd. has a 12 month low of $9.76 and a 12 month high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Roivant Sciences currently has a consensus rating of “Buy” and a consensus target price of $18.08.

Insider Buying and Selling at Roivant Sciences

In other news, CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now owns 163,264 shares of the company’s stock, valued at $1,702,843.52. The trade was a 58.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Eric Venker sold 218,041 shares of Roivant Sciences stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $10.42, for a total value of $2,271,987.22. Following the completion of the transaction, the chief operating officer now directly owns 896,869 shares of the company’s stock, valued at approximately $9,345,374.98. This represents a 19.56 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,388,170 shares of company stock valued at $27,612,299. 7.90% of the stock is currently owned by company insiders.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.